Home /

Vaccine maker earned record profits but delivered disappointment in return

By Sharon LaFraniere, Chris Hamby and Rebecca R. Ruiz
New York Times·
13 mins to read

Emergent BioSolutions was awarded a US$628 million federal contract with no competitive bidding. Top executives received big bonuses while factories mostly sat idle and tens of millions of Covid-19 doses were thrown away.

Record profits warranted record bonuses. That was the recommendation in January by executives at the biotech firm Emergent BioSolutions. The board of directors agreed, signing off on nearly US$8 million ($11 million) in cash and stock awards for five company leaders.

The bonuses arrived this spring even

Save